Creating a genetic profile of non-small-cell lung cancers may help predict prognosis and survival for individual patients, a Taiwanese study suggests.1 Researchers selected five genes as a signature of individual cancer specimens from 125 patients with this cancer, and found that this signature was an independent predictor of relapse-free and overall survival. The results of this study may lead to a refinement in the treatment of lung cancer, with only those patients having the high-risk gene signature being subjected to Cisplatin-based adjuvant chemotherapy. An accompanying editorial predicts that cancer genomics will expand into prospective trials designed to explore the response to standard and novel therapies of patients selected based on their molecular signature.2
Publication of your online response is subject to the Medical Journal of Australia's editorial discretion. You will be notified by email within five working days should your response be accepted.